| Advancing TROP-2-Targeted ADCs in HR+ Breast Cancer: Navigating Today and Shaping Tomorrow | 04/26/2025 | |
| Poster Pearl: Treating ER+/HER2- mBC with Elacestrant and Endocrine Therapy | 04/25/2025 | |
| Case: A Patient With High-Risk HR+/HER2- EBC Potentially Eligible for CDK4/6 and/or PARP Inhibitor | 04/24/2025 | |
| Case: A Patient With HR+/HER2- EBC at High-Risk for Recurrence | 04/11/2025 | |
| Maximizing Adherence and Persistence via Patient Engagement | 04/23/2025 | |
| Differentiating Safety Profiles of CDK4/6 Inhibitor Combination Regimens | 04/16/2025 | |
| High-Risk, HR+/HER2- EBC: Mastering Treatment Selection | 04/16/2025 | |
| Endpoints in Adjuvant Breast Cancer Trials: Implications for Clinical Practice | 04/19/2025 | |
| Treatment Intensification in HR+/HER2- EBC: Who and When? | 04/20/2025 | |
| Precision Timing: Unveiling the Impact of CDK4/6 Inhibition in Early HR+/HER2- Breast Cancer | | |
| Utilization and Management of Antibody-Drug Conjugates in Metastatic Breast Cancer: The Relationshi… | 12/20/2023 | |
| Current Standards and Future Opportunities for ADCs in Advanced/Metastatic Triple-Negative Breast C… | 01/02/2024 | |
| Exploring Efficacy & Overall Survival in the TROPiCS-02 Trial | | |
